These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

210 related items for PubMed ID: 35836202

  • 21.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 22. Prognostic value of fibroblast activation protein expressing tumor volume calculated from [68 Ga]Ga-FAPI PET/CT in patients with esophageal squamous cell carcinoma.
    Zhao L, Pang Y, Chen S, Chen J, Li Y, Yu Y, Huang C, Sun L, Wu H, Chen H, Lin Q.
    Eur J Nucl Med Mol Imaging; 2023 Jan; 50(2):593-601. PubMed ID: 36222855
    [Abstract] [Full Text] [Related]

  • 23. Evaluation of Prognostic Factors for Esophageal Squamous Cell Carcinoma Treated with Neoadjuvant Chemoradiotherapy Followed by Surgery.
    Hamai Y, Hihara J, Emi M, Furukawa T, Murakami Y, Nishibuchi I, Ibuki Y, Yamakita I, Kurokawa T, Nagata Y, Okada M.
    World J Surg; 2018 May; 42(5):1496-1505. PubMed ID: 29030675
    [Abstract] [Full Text] [Related]

  • 24. Detecting Interval Distant Metastases With 18F-FDG PET/CT After Neoadjuvant Chemoradiotherapy for Locally Advanced Esophageal Cancer.
    Kroese TE, Ruurda JP, Bakker AS, Jairam J, Mook S, van der Horst S, Meijer GJ, Haj Mohammad N, van Rossum PSN, van Hillegersberg R.
    Clin Nucl Med; 2022 Jun 01; 47(6):496-502. PubMed ID: 35384907
    [Abstract] [Full Text] [Related]

  • 25.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 26.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 27. Accuracy of detecting residual disease after neoadjuvant chemoradiotherapy for esophageal squamous cell carcinoma (preSINO trial): a prospective multicenter diagnostic cohort study.
    Zhang X, Eyck BM, Yang Y, Liu J, Chao YK, Hou MM, Hung TM, Pang Q, Yu ZT, Jiang H, Law S, Wong I, Lam KO, van der Wilk BJ, van der Gaast A, Spaander MCW, Valkema R, Lagarde SM, Wijnhoven BPL, van Lanschot JJB, Li Z.
    BMC Cancer; 2020 Mar 06; 20(1):194. PubMed ID: 32143580
    [Abstract] [Full Text] [Related]

  • 28. Role of surgical resection in complete responders on FDG-PET after chemoradiotherapy for locally advanced esophageal squamous cell carcinoma.
    Jeong Y, Kim JH, Kim SB, Yoon DH, Park SI, Kim YH, Kim HR, Jung HY, Lee GH, Ryu JS.
    J Surg Oncol; 2014 Apr 06; 109(5):472-7. PubMed ID: 24301552
    [Abstract] [Full Text] [Related]

  • 29. Total Lesion Glycolysis Ratio in Positron Emission Tomography/Computed Tomography Images During Neoadjuvant Chemotherapy Can Predict Pathological Tumor Regression Grade and Prognosis in Patients with Locally Advanced Squamous Cell Carcinoma of the Esophagus.
    Sonoda A, Yoshida N, Shiraishi S, Horinouchi T, Tokunaga R, Harada K, Iwatsuki M, Nagai Y, Baba Y, Iwagami S, Miyamoto Y, Baba H.
    Ann Surg Oncol; 2021 Jan 06; 28(1):167-174. PubMed ID: 32588261
    [Abstract] [Full Text] [Related]

  • 30.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 31. Prognostic Impact of Postoperative Lymph Node Metastases After Neoadjuvant Chemoradiotherapy for Locally Advanced Squamous Cell Carcinoma of Esophagus: From the Results of NEOCRTEC5010, a Randomized Multicenter Study.
    Leng X, He W, Yang H, Chen Y, Zhu C, Fang W, Yu Z, Mao W, Xiang J, Chen Z, Yang H, Wang J, Pang Q, Zheng X, Liu H, Yang H, Li T, Zhang X, Li Q, Wang G, Mao T, Guo X, Lin T, Liu M, Fu J, Han Y.
    Ann Surg; 2021 Dec 01; 274(6):e1022-e1029. PubMed ID: 31855875
    [Abstract] [Full Text] [Related]

  • 32. Interval Metastases After Neoadjuvant Chemoradiotherapy for Patients with Locally Advanced Esophageal Cancer: A Multicenter Observational Cohort Study.
    van der Zijden CJ, van der Sluis PC, Mostert B, Nuyttens JJME, van Lanschot JJB, Spaander MCW, Valkema R, Coene PPLO, Dekker JWT, Fiets WE, Hartgrink HH, Hazen WL, Kouwenhoven EA, Nieuwenhuijzen GAP, Rosman C, van Sandick JW, Sosef MN, van der Zaag ES, Lagarde SM, Wijnhoven BPL.
    Ann Surg Oncol; 2024 Nov 01; 31(12):7759-7766. PubMed ID: 39068317
    [Abstract] [Full Text] [Related]

  • 33.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 34.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 35.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 36.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 37. Favorable versus unfavorable prognostic groups by post-chemoradiation FDG-PET imaging in node-positive esophageal squamous cell carcinoma patients treated with definitive chemoradiotherapy.
    Yap WK, Chang YC, Hsieh CH, Chao YK, Chen CC, Shih MC, Hung TM.
    Eur J Nucl Med Mol Imaging; 2018 May 01; 45(5):689-698. PubMed ID: 29188300
    [Abstract] [Full Text] [Related]

  • 38.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 39. Predictions of Pathological Features and Recurrence Based on FDG-PET Findings of Esophageal Squamous Cell Carcinoma after Trimodal Therapy.
    Hamai Y, Emi M, Ibuki Y, Murakami Y, Nishibuchi I, Nagata Y, Furukawa T, Kurokawa T, Ohsawa M, Yoshikawa T, Okada M.
    Ann Surg Oncol; 2020 Oct 01; 27(11):4422-4430. PubMed ID: 32405978
    [Abstract] [Full Text] [Related]

  • 40. Improved prognosis with induction chemotherapy in pathological complete responders after trimodality treatment for esophageal squamous cell carcinoma: Hypothesis generating for adjuvant treatment.
    Lu SL, Hsu FM, Tsai CL, Lee JM, Huang PM, Hsu CH, Lin CC, Chang YL, Hsieh MS, Cheng JC.
    Eur J Surg Oncol; 2019 Aug 01; 45(8):1498-1504. PubMed ID: 30910457
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 11.